- Home
- Diagnostics
- NGS Panels
- Oncology
Oncology
Genetic testing for hereditary and somatic cancers can provide life-changing results in affected patients and their relatives, accompanied by potential actionable steps for genetic-related cancers. With many different applications of genetic testing to detect and care for cancer, we can guide you in selecting the right options to enhance the treatment of your patients suffering from hereditary cancers. Having identified genetic variants associated with oncological diseases in more than 200 different genes, we can provide a comprehensive range to foster cancer diagnosis, prognosis, treatment selection, and monitoring.
BRCA1, BRCA2 panel
Breast cancer is the most common type of cancer in woman constituting around 25% of all females cases. Mutations in BRCA1 and BRCA2 can increase the risk of developing cancer.
BRCA1, BRCA2 panel (germline):
| No. of genes: | 2 |
| TAT: | 15 days |
| Coverage: | ≥100% ≥20x |
| Details: | Panel includes only NGS sequencing |
BRCA1, BRCA2 panel Combi (germline):
| No. of genes: | 2 |
| TAT: | 15 days |
| Coverage: | ≥100% ≥20x |
| Details: | Panel includes NGS sequencing and MLPA |
BRCA1, BRCA2 panel (somatic):
| No. of genes: | 2 |
| TAT: | 10 days |
| Coverage: | variable |
| Details: | Panel for somatic mutation analysis |
COMMON SYNDROMES AND DISORDERS COVERED
BRCA1, BRCA2
CentoBreast®
CentoBreast® detects mutations in the BRCA1 and BRCA2 genes, which are the most common hereditary causes for breast cancer. In addition, our panel includes other genes such as ATM, BRIP1, CHEK2, PALB2, RAD51, etc. which have also been associated with increased cancer risk. Breast cancer is one of the most common cancers in the world affecting ~12.5% of women during their lifetime, with 5–10% of these patients having a hereditary form.
| No. of genes: | 30 |
| TAT: | 15 days |
| Coverage: | ≥99.5% ≥20x |
| Details: | CNV included; germline |
COMMON SYNDROMES AND DISORDERS COVERED
Breast cancer
Ovarian cancer
CentoCancer®
Each gene in CentoCancer® has been carefully selected based on its risk potential in the development of one or more of the following cancers: breast, ovarian, colorectal, gastric, thyroid, endometrial, pancreatic, melanoma, renal, and prostate. This panel is appropiate for patients with positive personal history of early-onset cancer, rare cancer, bilateral cancer, or multiple primary cancers. It is also intended for patients where the suspected familial cancer risk is not covered by a single targeted panel.
| No. of genes: | 70 |
| TAT: | 15 days |
| Coverage: | ≥99.5% ≥20x |
| Details: | CNV included; germline |
COMMON SYNDROMES AND DISORDERS COVERED
Breast cancer
CentoColon extended
Colorectal cancer
Endometrial cancer
Familial adenomatous polyposis
Gastric cancer
Gastrointestinal stromal tumor
Hereditary Paraganglioma/ Pheochromocytoma
Melanoma
Ovarian cancer
Pancreatic cancer
Paragangliomas/Pheochromocytoma/Gastrointestinal stromal
Prostate cancer
Renal cancer
Skin cancer
Thyroid cancer
Uterine cancer
CentoCancer® comprehensive
CentoCancer® comprehensive is our most extensive cancer panel, offering complete answers to help you choose the best possible therapeutic approach for your patients. Each gene in this panel has been carefully selected based on its risk potential in the development of one or more of the following cancers: breast, ovarian, colorectal, gastric, thyroid, endometrial, pancreatic, melanoma, renal, and prostate.
| No. of genes: | 111 |
| TAT: | 15 days |
| Coverage: | ≥99.5% ≥20x |
| Details: | CNV included; germline |
COMMON SYNDROMES AND DISORDERS COVERED
Beckwith-Wiedemann syndrome
Retinoblastoma
Rothmund-Thomson syndrome (Type 2)
CentoColon
CentoColon detects genes that are associated with colon, pancreatic, and gastric cancer.
| No. of genes: | 33 |
| TAT: | 15 days |
| Coverage: | ≥99.5% ≥20x |
| Details: | CNV included; germline |
COMMON SYNDROMES AND DISORDERS COVERED
Colorectal cancer
Familial adenomatous polyposis
Gastric cancer
Hereditary nonpolyposis colorectal cancer
Pancreatic cancer
Myeloid tumor panel
Our myeloid tumor panel targets important regions within 22 genes that are frequently mutated in myeloid malignancies. Myeloid malignancies are clonal diseases of hematopoietic progenitor cells. Myeloid tumors represent the fourth most frequently diagnosed cancer in economically developed countries. The majority of myeloid tumors contain high numbers of somatic mutations, which are genetic changes that are not inherited but created within the tumor itself. Unlike inherited “germline” mutations, these somatic mutations are not transmitted to offspring. Somatic mutations significantly contribute to the pathogenesis, progression, and prognosis of myeloid malignancies. Whole genome sequencing in several patients with myeloproliferative disorders pointed at several genes and variants, clearly associated in patients affected with myeloproliferative syndromes.
| No. of genes: | 22 |
| TAT: | 10 days |
| Coverage: | >97% >200x |
| Details: | somatic |
COMMON SYNDROMES AND DISORDERS COVERED
Acute myeloid leukemia
Chronic myeloid leukemia
Chronic myelomonocytic leukemia
Juvenile myelomonocytic leukemia
Myelodysplastic syndrome
Myeloid tumor
Myeloproliferative neoplasms
Solid tumor panel
Our solid tumor panel provides full sequencing of 106 selected cancer-associated genes as well as the hotspot analysis of relevant cancer regions in 43 genes. It detects over 5,000 validated oncogenic variants and includes the latest evidence-based variants associated with treatment decisions in solid tumors. The panel has more than 25 genes with approved targeted therapies or those that are being currently tested in clinical trials. Furthermore, somatic variants with an impact on prognosis of the individual tumor or on the efficacy of standard anti-tumor therapy are captured. It covers more than 100 different types of somatic cancers, including adrenal, colon, hepatic, prostate, renal, skin, testicular, thyroid, glioma, esophageal, endometrial, and breast, among others. The panel provides a better understanding of tumor behavior as well as its likelihood to respond to a treatment, contributing to tailored medicine for the patient, thus frequently leading to a better outcome or reduced adverse effects.
| No. of genes: | 149 |
| TAT: | 10 days |
| Coverage: | >97% >200x |
| Details: | somatic |